Takahiro Fujita

BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors.

BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors.

BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors.